Detail akcie Genflow Bio Rg online

Business Summary: Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product pipeline includes GF-1002, GF-1003, GF-1004, GF-1005 and GF-1006. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-1004 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-1003 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Genflow Biosciences PLC revenues was not reported. Net loss increased 41% to L738K. Higher net loss reflects Other Operating Income decrease of 69% to L245K (income), Total administrative expenses - Balanc increase of 29% to L227K (expense).